Neuroschistosomiasis is a rare entity, it can cause cerebral or spinal cord involvement. high clinical suspicion is needed to diagnose it and rapid treatment is needed to prevent complications.

Bosutinib is approved as first line therapy for treatment of chronic phase CML and also in patients who are either resistant or intolerant to previous TKI. We present a 59 year old male who was intolerant to 2 TKI but showed excellent hematological and major molecular response to Bosutinib.